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IV thrombolysis and renal function
ABSTRACT
Objective: To investigate the association of renal impairment on functional outcome and compli-
cations in stroke patients treated with IV thrombolysis (IVT).
Methods: In this observational study, we compared the estimated glomerular filtration rate (GFR)
with poor 3-month outcome (modified Rankin Scale scores 3–6), death, and symptomatic intra-
cranial hemorrhage (sICH) based on the criteria of the European Cooperative Acute Stroke Study
II trial. Unadjusted and adjusted odds ratios (ORs) with 95% confidence intervals (CIs) were
calculated. Patients without IVT treatment served as a comparison group.
Results: Among 4,780 IVT-treated patients, 1,217 (25.5%) had a lowGFR (,60mL/min/1.73m2). A
GFR decrease by 10 mL/min/1.73 m2 increased the risk of poor outcome (OR [95%CI]): (ORunadjusted
1.20 [1.17–1.24]; ORadjusted 1.05 [1.01–1.09]), death (ORunadjusted 1.33 [1.28–1.38]; ORadjusted
1.18 [1.11–1.249]), and sICH (ORunadjusted 1.15 [1.01–1.22]; ORadjusted 1.11 [1.04–1.20]). Low
GFR was independently associated with poor 3-month outcome (ORadjusted 1.32 [1.10–1.58]), death
(ORadjusted 1.73 [1.39–2.14]), and sICH (ORadjusted 1.64 [1.21–2.23]) compared with normal GFR
(60–120 mL/min/1.73 m2). Low GFR (ORadjusted 1.64 [1.21–2.23]) and stroke severity (ORadjusted
1.05 [1.03–1.07]) independently determined sICH. Compared with patients who did not receive IVT,
treatment with IVT in patients with low GFR was associated with poor outcome (ORadjusted 1.79
[1.41–2.25]), and with favorable outcome in those with normal GFR (ORadjusted 0.77 [0.63–0.94]).
Conclusion: Renal function significantly modified outcome and complication rates in IVT-treated
stroke patients. Lower GFR might be a better risk indicator for sICH than age. A decrease of GFR
by 10 mL/min/1.73 m2 seems to have a similar impact on the risk of death or sICH as a 1-point-
higher NIH Stroke Scale score measuring stroke severity. Neurology® 2013;81:1780–1788
GLOSSARY
CI 5 confidence interval; CKD-EPI 5 Chronic Kidney Disease Epidemiology Collaboration; ECASS 5 European Cooperative
Acute Stroke Study; GFR 5 glomerular filtration rate; ICH 5 intracranial hemorrhage; IVT 5 IV thrombolysis; MDRD 5
Modification of Diet in Renal Disease;mRS5modified Rankin Scale; NIHSS5NIH Stroke Scale; NINDS5 National Institute
of Neurological Disorders and Stroke; OR 5 odds ratio; SCr 5 serum creatinine; sICH 5 symptomatic intracranial
hemorrhage.
Renal dysfunction is associated with higher mortality in stroke patients1–6 and with an increased
risk of ischemic and hemorrhagic stroke in the general population.7,8 In stroke patients treated
with IV thrombolysis (IVT), the impact of renal function on outcome or complications remains
to be clarified. In 3 studies, impaired kidney function was associated with unfavorable 3-month
outcome,9–11 but not in a fourth one.12 Furthermore, renal dysfunction was reported to be a risk
factor for symptomatic intracranial hemorrhage (sICH) as a complication of IVT in one study,10
but this finding could not be confirmed by others.9,11,12 Interestingly, renal hyperfiltration was
reportedly associated with increased mortality according to 2 recent reports in stroke patients in
general.2,4 It remains unclear whether this association holds true for IVT-treated patients.
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Using pooled individual data from 4,780 pa-
tients treated with IVT, we studied whether
impaired renal function regarding low or high
glomerular filtration rate (GFR) was indepen-
dently associated with functional 3-month out-
come and increased risk of sICH, and we
aimed to provide quantitative estimates for these
associations. Second, we studied whether high
GFR (renal hyperfiltration) was associated with
worse functional outcome or increased frequency
of intracranial hemorrhage (ICH). Third, we
added a cohort of 1,427 stroke patients treated
without IVT to assess the interaction between
renal insufficiency and IVT treatment.
METHODS As a joint initiative of 11 European stroke centers,
we designed a large collaborative cohort study to address several
important IVT-related clinical research questions. In this study,
we investigated the impact of renal function on outcomes of stroke
patients receiving IVT. All participating centers treated patients
with acute ischemic stroke with IVT according to current guide-
lines (http://www.eso-stroke.org/recommendations.php?cid59).
Data from individual patients were collected with a standard-
ized form with predefined variables as it was used in previous stud-
ies.13,14 Local study investigators completed the forms systematically
using prospectively ascertained in-hospital IV ischemic stroke
thrombolysis registries. Completed forms from all centers were
compiled in the coordinating center Basel, where the analysis of
the pooled data was performed, as described previously.13,14
The following prospectively ascertained variables were used: age,
sex, initial stroke severity as assessed using the NIH Stroke Scale
(NIHSS),15 blood pressure before IVT, onset to treatment, initial
serum creatinine (SCr) and glucose values in blood serum, etiology
according to the TOAST (Trial of Org 10172 in Acute Stroke
Treatment) criteria,16 and vascular risk factors according to prede-
fined criteria.17 Post hoc, we added prior treatment with antithrom-
botic agents (antiplatelet agents and anticoagulants). Functional
outcome was assessed by outpatient visits or telephone calls using
the modified Rankin Scale (mRS) at 3 months. There was monitor-
ing for ICH by follow-up CT or MRI as done in prior research.14
Each center reported on the period for which they had pro-
spectively collected data on consecutive patients up to December
31, 2011 (table e-1 on the Neurology® Web site at www.
neurology.org). Patients were excluded if 1) they had a final
diagnosis other than acute ischemic stroke (i.e., patients with
stroke mimics),18 2) their SCr values were not available, or 3)
3-month outcome data were not available.
Primary outcome measures were poor functional 3-month
outcome, defined as mRS scores 3 to 6, death, and sICH accord-
ing to criteria of the European Cooperative Acute Stroke Study II
(ECASS-II) trial (sICHECASS-II).19 Secondary outcome measures
were unfavorable outcome (mRS scores 2–6), and ICH according
to other definitions: all ICH (ICHALL), sICH based on the cri-
teria of the National Institute of Neurological Disorders and
Stroke trial (sICHNINDS), and fatal ICH (sICHFATAL).20
GFR as a measure of renal function was calculated applying
the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation: GFR 5 144 3 (SCr/0.7)20.329 3
(0.993)age (if female and SCr #0.7 mg/dL), GFR 5 144 3
(SCr/0.7)21.209 3 (0.993)age (if female and SCr $0.7 mg/dL),
GFR 5 141 3 (SCr/0.9)20.411 3 (0.993)age (if male and SCr
#0.9 mg/dL), and GFR 5 141 3 (SCr/0.9)21.209 3 (0.993)age
(if male and SCr $0.9 mg/dL).21
In addition, we assessed the interaction of renal insufficiency
and IVT treatment between patients treated with and without
IVT. A total of 1,427 patients without IVT treatment admitted
to hospital within 6 hours after symptom onset were included
in the analysis. Data were collected from 3 stroke registries (Lau-
sanne between January 1, 2003 and December 31, 2012; Brescia
between April 2007 and February 2010; and Bernese between
January 1, 2004 and June 30, 2011).22–24
Post hoc, in a subset of patients, data of early hypodensity on
initial CT scan (present vs absent) and data of recanalization (par-
tial/complete vs no recanalization of the main intracranial cerebral
artery) were included in subgroup analyses. These were restricted
to patients from centers routinely collecting such data (i.e., Basel
and Lausanne).
Standard protocol approvals, registrations, and patient
consents. The study was approved by the ethics committee in
Basel, Switzerland. The requirement for additional local ethical
approval differed among participating centers and was obtained
if required.
Statistical analyses. Statistical analysis was performed using
SPSS (version 19.0 for Windows; SPSS Inc., Chicago, IL). Renal
function as quantified by the GFR was compared with outcome
measures as a continuous variable and as a categorical variable.
For the latter, patients’ GFRs were divided into 3 groups using
thresholds reported in prior research4: 1) low GFR,60 mL/min/
1.73 m2, 2) normal GFR 60 to 120 mL/min/1.73 m2, and 3) high
GFR.120 mL/min/1.73 m2. Post hoc, we added a category very
low GFR defined as ,30 mL/min/1.73 m2. Data were summa-
rized as median (6 interquartile range). Normal GFR served as
the reference group. We compared demographic and clinical
baseline characteristics among patients in the 3 GFR groups using
Fisher exact test or the x2 test for categorical variables and the
Mann-Whitney U test for continuous variables. The association
between GFR (both as a continuous variable and as a categorical
variable as defined above) and each outcome was estimated by
calculating the odds ratios (ORs) with 95% confidence intervals
(CIs) using binary logistic regression models. In the multivariate
analysis, the models were adjusted for all variables with p value
,0.1 in the univariate analyses. The adjustments in the models
comparing “high GFR” with “normal GFR” as well as “IVT” with
“non-IVT” were restricted to “age” and “NIHSS score”—to avoid
overfitting in a small sample size.
In addition, we rendered analyses focusing on the shape of the
relation between the probability of the primary outcome measures
and GFR further including sex, age, and NIHSS score as covariates.
For GFR and numerical covariates (i.e., age and NIHSS score), lin-
ear, quadratic, and cubic terms were considered a priori, but models
were then simplified by successively eliminating highest order
terms, which increased the Bayesian information criterion. The
information criteria were applied to derive a parsimonious final
model (minimizing the Bayesian information criterion).
RESULTS IVT population: Baseline characteristics and
regression analyses. Data were suitable for analysis in
4,780 (97.2%) of the 4,916 IVT-treated patients
included in the entire database; 48 patients lacking cre-
atinine values and 88 patients with missing 3-month
outcome data were excluded from the present analysis.
Among eligible patients, 1,217 (25.5%) had low GFR,
3,504 (73.3%) a normal GFR, and 59 (1.2%) a high
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GFR. Baseline characteristics and number of outcome
events are presented in table 1. Patients with low GFR
were a median of 10 years older, were more likely to be
female, had a higher NIHSS score, and had more vas-
cular risk factors than patients with normal GFR.More
patients with low GFR had large-artery atherosclerosis
as underlying stroke etiology than patients with normal
GFR. In contrast, patients with high GFR were on
average 33 years younger, had a lower median NIHSS
score, and had fewer risk factors than patients with
normal GFR (table 1).
All outcome events occurred significantly more
often in the low GFR group than in the normal
GFR group. Patients in the high GFR group had a
better outcome at 3 months, but did not otherwise
significantly differ from the normal GFR group.
The distribution of the unadjusted 3-month outcome
and the frequency of sICHECASS-II stratified to the 3
GFR groups are presented in figure 1.
In univariate analyses, decreasing GFR (by 10 mL/
min/1.73 m2) and low GFR were significantly asso-
ciated with all primary and all secondary outcome
measures (tables 2 and e-2). High GFR was associated
with a lower frequency of poor outcomes (27.1% vs
40.7%, p 5 0.044) and a trend toward a lower fre-
quency of unfavorable outcomes (45.8% vs 58.0%,
p 5 0.064) compared to patients with normal GFR.
High GFR was neither associated with death nor ICH
in all categories (tables 2 and e-2).
After adjustment for age, sex, stroke severity
(NIHSS score), blood glucose concentration, systolic
blood pressure, atrial fibrillation, onset to treatment,
hypertension, diabetes, hypercholesterolemia, smok-
ing, coronary artery disease, prior stroke, and prior
treatment with antithrombotics, every decrease of
GFR by 10 mL/min/1.73 m2 increased the risk of
poor outcome (ORadjusted 1.05, 95% CI 1.01–1.09,
p 5 0.017), death (ORadjusted 1.18, 95% CI 1.11–
1.24, p, 0.001), and sICHECASS-II (ORadjusted 1.11,
95% CI 1.04–1.20, p5 0.003). After adjustment for
the aforementioned variables, low GFR was still asso-
ciated with poor outcome (ORadjusted 1.32, 95% CI
1.10–1.58, p 5 0.003) and death (ORadjusted 1.73,
95% CI 1.39–2.14, p , 0.0001). Interestingly, for
sICHECASS-II, stroke severity (ORadjusted 1.05, 95%
CI 1.03–1.07, p , 0.001) and low GFR (ORadjusted
1.64, 95% CI 1.21–2.23, p 5 0.001) were the only
independent determinants, while all other covariates
including age had no significant impact.
Post hoc analysis revealed that in patients with
very low GFR vs normal GFR, the odds for poor out-
come and for death were higher than for low GFR
(table 3). For high GFR, after adjustment for age
and stroke severity, there was no longer an association
with functional outcome measures (tables 3 and e-3).
Based on a parsimonious final model, figure e-1 shows
an almost linear association between decreasing GFR
with increasing risk of “poor outcome” and “death,”
adjusted for age, sex, and NIHSS score.
IVT population: Subgroup analyses. In a subset of pa-
tients (n 5 942 from Basel and Lausanne), data of
early hypodensity on initial CT scan and recanalization
were available. Patients with early hypodensity on ini-
tial CT scan were at significantly increased risk of poor
outcome (ORunadjusted 2.48, 95% CI 1.88–3.23, p ,
0.001), death (ORunadjusted 2.24, 95% CI 1.55–3.23,
p, 0.001), and sICHECASS-II (ORunadjusted 2.30, 95%
CI 1.15–4.56, p 5 0.018). After adjustment for renal
function, both low GFR and presence of early hypo-
density on initial CT had significant impact on all
primary outcome events.
Low GFR did not modify recanalization rates in
patients with initial occlusion of a main intracranial
artery (ORunadjusted 0.95, 95% CI 0.61–1.47, p 5
0.803). Female sex (ORunadjusted 0.48, 95% CI
0.32–0.72, p , 0.001), lower NIHSS score (each
point) at stroke onset (ORunadjusted 0.96, 95% CI
0.93–0.99, p 5 0.008), and absence of early hypo-
density on initial CT (ORunadjusted 0.61, 95% CI
0.41–0.92, p 5 0.019) were determinants of partial
or complete recanalization after IVT.
IVT-treated compared with non–IVT-treated patients. In
the non-IVT group, 1,427 patients were eligible for
analysis. Comparison of baseline characteristics
between patients treated with and without IVT is pre-
sented in table 1. IVT-treated patients had more
severe strokes than patients in the non-IVT group.
Median age and onset-to-treatment or onset-to-door
time did not differ significantly between the 2 groups.
IVT-treated patients with normal GFR had lower
risk of a poor 3-month outcome (ORadjusted 0.77,
95% CI 0.63–0.94, p 5 0.010) or death (ORadjusted
0.71, 95% CI 0.54–0.95, p5 0.020) than patients not
treated with IVT. In patients with low GFR, the odds
for poor outcome (ORadjusted 1.79, 95% CI 1.41–2.25,
p , 0.001) or death (ORadjusted 1.51, 95% CI 1.15–
1.98, p 5 0.003) were higher in the IVT than in the
non-IVT group. Compared with the non-IVT group,
the risk of sICHECASS-II was higher in IVT-treated
patients with normal GFR (ORadjusted 5.31, 95% CI
2.33–12.12, p, 0.001) and with low GFR (ORadjusted
21.25, 95% CI 4.85–99.03, p , 0.001).
DISCUSSION This cohort study, the largest thus
far to investigate the impact of renal function in
IVT-treated stroke patients, revealed the following
main findings: 1) GFR as a continuous or categorical
variable was a determinant of outcome and complica-
tions in IVT; 2) impaired renal function (i.e., GFR
,60 mL/min/1.73 m2) independently predicted
poor functional outcome, death, and sICH; 3) high
1782 Neurology 81 November 12, 2013
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Table 1 Clinical characteristics of IVT-treated and non–IVT-treated stroke patients stratified to low and high vs normal GFR (reference group) and in comparison between treatment groups
Baseline characteristics All Low GFR High GFR Normal GFR compared with:
IVT treatment n 5 4,780 n 5 1,217 n 5 59 n 5 3,504
Low
GFR
High
GFRNon-IVT treatment n 5 1,427 n 5 465 n 5 17 n 5 946
Group p Value p Value p Value p Value p Value
Age, y, median (IQR) IVT 71 (60–79) 0.059 78 (72–83) 0.003 35 (24–54) 0.529 68 (57–76) ,0.001 ,0.001
Non-IVT 72 (59–80) 80 (74–85) 30 (25–45) 66 (56–76) ,0.001 ,0.001
Men, n (%) IVT 2,657 (55.6) ,0.001 517 (42.5) 0.001 33 (55.9) 0.835 2,106 (60.1) ,0.001 0.514
Non-IVT 882 (61.8) 241 (51.8) 10 (58.8) 631 (66.7) ,0.001 ,0.001
Stroke severity, NIHSS score, median (IQR) IVT 11 (7–17) ,0.001 12 (8–18) ,0.001 10 (7–17) ,0.001 11 (6–16) ,0.001 0.887
Non-IVT 4 (2–10) 6 (3–14) 3 (2–6) 4 (2–8) ,0.001 0.333
Systolic blood pressure, mm Hg, median (IQR) IVT 154 (140–171) 0.420 158 (140–176) 0.512 130 (120–149) 0.381 154 (139–170) ,0.001 ,0.001
Non-IVT 153 (135–172) 159 (141–180) 131 (126–151) 151 (135–170) ,0.001 0.010
Onset to treatment (or to door), min, median (IQR) IVT 140 (105–177) 0.096 140 (105–175) 0.022 134 (106–170) 0.008 140 (105–178) 0.855 0.454
Non-IVT 135 (77–220) 128 (73–208) 188 (134–235) 137 (78–226) 0.139 0.129
Creatinine on admission, mmol/L, median (IQR) IVT 81 (68–97) ,0.001 111 (96–131) 0.001 50 (36–62) 0.206 74 (64–86) ,0.001 ,0.001
Non-IVT 86 (71–105) 116 (101–134) 51 (47–61) 77 (68–88) ,0.001 ,0.001
Glucose on admission, mg/dL, median (IQR) IVT 6.7 (5.8–8.0) ,0.001 7.0 (6.0–8.7) ,0.001 5.8 (5.2–6.7) 0.904 6.5 (5.7–7.8) ,0.001 0.001
Non-IVT 6.4 (5.6–7.7) 6.5 (5.7–8.0) 5.8 (5.3–6.3) 6.4 (5.5–7.6) 0.039 0.076
Prior antithrombotics, n (%) IVT 2,076 (43.4) ,0.001 721 (59.1) 0.005 11 (18.4) 0.002 1,344 (38.4) ,0.001 0.002
Non-IVT 776 (54.3) 308 (66.2) 9 (52.9) 459 (48.5) ,0.001 ,0.001
Atrial fibrillation, n (%) IVT 1,318 (27.8) ,0.001 480 (39.7) 0.132 9 (15.5) 0.095 829 (23.9) ,0.001 0.162
Non-IVT 258 (18.1) 137 (29.5) 1 (5.9) 121 (12.8) ,0.001 0.097
Hypertension, n (%) IVT 3,169 (66.5) 0.472 985 (81.0) 0.513 13 (22.0) 0.70 2,171 (62.2) ,0.001 ,0.001
Non-IVT 829 (58.1) 343 (73.8) 3 (17.6) 483 (51.1) ,0.001 0.001
Smoking, n (%) IVT 970 (21.3) 0.037 117 (10.3) 0.278 22 (38.6) 0.752 831 (24.7) ,0.001 0.017
Non-IVT 280 (19.6) 44 (9.5) 7 (41.2) 229 (24.2) ,0.001 0.218
Hypercholesterolemia, n (%) IVT 1,657 (37.4) ,0.001 443 (40.9) ,0.001 9 (15.5) 0.836 1,205 (36.6) ,0.001 0.001
Non-IVT 530 (37.1) 199 (42.8) 2 (11.8) 329 (34.8) 0.005 0.008
Diabetes mellitus, n (%) IVT 891 (18.7) 0.059 301 (24.8) 0.572 5 (8.5) 0.234 585 (16.8) 0.011 0.111
Non-IVT 212 (14.8) 97 (20.9) 1 (5.9) 115 (12.2) ,0.001 0.117
Coronary artery disease, n (%) IVT 830 (17.4) 0.243 319 (26.3) 0.035 4 (6.8) 0.897 507 (14.5) ,0.001 0.131
Non-IVT 211 (14.8) 89 (19.1) 1 (5.9) 121 (12.8) 0.001 0.346
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GFR (.120 mL/min/1.73 m2) was neither associated
with poor functional outcome nor with death or
sICH; and 4) in contrast to patients with normal
GFR, patients with renal impairment received no
beneficial effect with IVT treatment compared with
nonthrombolyzed patients.
The impact of renal function on functional out-
come and hemorrhagic complications in IVT-treated
patients had not been satisfactorily investigated. We
are aware of solely 4 studies addressing these points,
with inconsistent results. These discrepancies may
be attributable to the relatively small sample sizes
(n 5 74, 196, 229, and 578 patients).9–12 Renal
impairment independently predicted poor functional
outcome in 3 studies9–11 and death in 2 studies.9,10 A
fourth study could not confirm these findings.12 Fur-
thermore, in one study, sICH occurred significantly
more often in patients with low GFR,10 whereas 3
other studies could not find such an association.9,11,12
This large multicenter study with 4,780 IVT-treated
patients had the power to address this lack of informa-
tion: renal function is a strong predictor for poor func-
tional outcome, death, and sICH. In patients with
GFR ,60 mL/min/1.73 m2, the risk of poor func-
tional outcome (mRS scores 3–6) increased by 34%
at 3 months compared with patients with normal
GFR (GFR 60–120 mL/min/1.73 m2). The risk of
death increased by at least 39% and may even reach
114% (i.e., 95% CI). Symptomatic ICH—according
to the ECASS-II and NINDS criteria—occurred 1.7-
and 1.4-fold more frequently.
A decrease in GFR by 10 mL/min/1.73 m2 had at
least the same predictive value as a 1-point change in
the NIHSS for death and sICH. These results show
that impaired renal function significantly modified
outcome and complication rates in patients treated
with IVT and should therefore be considered in
future IVT studies and registries.
Interestingly, age did not independently predict
the risk of sICH as low GFR and stroke severity were
the only independent covariates. This unexpected
observation might be explained by the fact that esti-
mation of the GFR by the CKD-EPI formula con-
tains the variable age. Alternatively, lower GFR
might be a better indicator for impaired health status
than higher age. In addition, antithrombotics,
although more often used in patients with renal
impairment, did not independently influence the risk
of sICH.
Regarding possible explanations of our key find-
ings, renal dysfunction was a major risk factor for car-
diovascular complications after a myocardial
infarction25; in analogy to these findings, putative
mechanisms by which renal dysfunction affects out-
come and complications in IVT-treated patients may
include renal anemia, oxidative stress, inflammation,
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endothelial dysfunction, and paradoxical effects on
hemostasis (i.e., bleeding and thrombosis).25,26
As another novel aspect, we investigated the impact
of renal hyperfiltration (.120 mL/min/1.73 m2) on
outcome in IVT-treated patients. Previously, hyperfiltra-
tion was associated with a higher mortality rate in general
patients (i.e., not an IVT-treated stroke population) at
30 days, and at long-term follow-up in 2 studies.2,4 We
found no increased risk of poor functional outcome,
death, or sICH in patients with hyperfiltration. In turn,
in the univariate analysis, hyperfiltration was associated
with a lower chance of a poor outcome, which however
disappeared after adjustment for age and stroke severity.
The number of patients with hyperfiltration in the 2
studies was 54 and 106, but their proportion was higher
(4.6% and 11.1%) than in our study (1.2%). These
differences might be attributable to variations in the
studied stroke populations (e.g., age distribution, IVT
treatment) or methodologic differences such as the for-
mula used to estimate GFR (i.e., Modification of Diet in
Renal Disease [MDRD]2,4 and CKD-EPI in our study).
The MDRD formula was developed by studying pa-
tients with CKD and was criticized as being inaccurate
at higher GFR values.21 Recently, the CKD-EPI formula
predicted clinical risk more accurately than the MDRD
formula across a broad spectrum of patients, including
patients with higher GFR values.27
To clarify whether patients with impaired renal
function still benefit from IVT, we included in the
analysis a group of stroke patients not treated with
IVT, who were admitted to the hospital within
6 hours after stroke onset. As expected, the control
group had a marked lower median NIHSS score at
stroke onset (4 vs 11), but the onset-to-treatment or
onset-to-door time did not differ significantly.
Our post hoc nonrandomized comparison with a
cohort of patients treated without IVT revealed that
patients with normal GFR benefited from IVT treat-
ment. The reduction in odds of poor outcome was
similar to a meta-analysis of 6 randomized controlled
IVT trials (OR 0.80, 95% CI 0.69–0.93, p 5 0.003
vs OR 0.77, 95% CI 0.63–0.94, p 5 0.010).28
In contrast, patients with renal impairment did
not benefit from IVT treatment. One explanation
could be that patients with renal insufficiency have
reduced fibrinolysis rates, due to less clot permeability
and higher clot rigidity.29,30 However, in our sub-
group of IVT-treated patients with initial occlusion
of a main intracranial artery, renal function had no
impact on recanalization rates. Because of methodo-
logic limitations, we urge cautious interpretation of
these findings.
Strengths of this study include 1) the large sample
size addressing the impact of renal function on out-
come in IVT-treated patients, which reduces the odds
for false-positive or -negative findings and allowed
corrections for several confounding variables; 2) the
systematic and standardized assessment of data collec-
tion with only a few missing data (2.77%); and 3) the
inclusion of non–IVT-treated patients as a compari-
son group.
Nevertheless, we are aware of the following limita-
tions. First, data came from registries that were not
monitored, and the cohorts (IVT vs non-IVT groups)
differed in baseline characteristics and were non-
randomized. Because observational nonrandomized
studies have a higher risk of bias, we urge a cautious
interpretation of these comparisons. Second, even if
the new CKD-EPI formula has a higher accuracy
than the MDRD formula, neither has been validated
in the elderly so far.3,27 Furthermore, we did not cor-
rect for race, and information about the cause of renal
insufficiency was not available. Third, although we
included factors associated with both renal impair-
ment and outcome in the multivariate analysis, it is
possible that these adjustments were not complete.
Figure 1 GFR-depending proportion of patients with (A) unadjusted 3-month
outcome, and (B) occurrence of sICH
ECASS5 European Cooperative Acute Stroke Study; GFR5 glomerular filtration rate; mRS
5 modified Rankin Scale; sICH 5 symptomatic intracranial hemorrhage.
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Table 2 Univariate analysis of clinical characteristics in patients treated with IVT
Predictor for Poor outcome (mRS 3–6) Death sICHECASS-II
Age (each year) 1.05 (1.04–1.05)a 1.07 (1.06–1.08)a 1.02 (1.01–1.03)a
Sex 1.53 (1.37–1.72)a 1.36 (1.16–1.60)a 1.09 (0.85–1.41)
NIHSS (each point) 1.19 (1.18–1.20)a 1.15 (1.14–1.17)a 1.06 (1.04–1.08)a
Glucose (each mg/dL) 1.12 (1.01–1.15)a 1.11 (1.08–1.14)a 1.06 (1.01–1.10)a
Systolic blood pressure (each mm Hg) 1.004 (1.002–1.007)a 1.006 (1.003–1.010)a 1.00 (0.99–1.01)
Onset to treatment (each minute) 1.001 (1.000–1.002)b 1.000 (0.999–1.001) 1.000 (0.998–1.002)
Atrial fibrillation 1.96 (1.72–2.23)a 1.97 (1.67–2.33)a 1.49 (1.14–1.94)a
Diabetes mellitus 1.62 (1.40–1.88)a 1.66 (1.38–2.00)a 1.54 (1.15–2.07)a
Hypertension 1.49 (1.32–1.68)a 1.77 (1.47–2.13)a 1.75 (1.30–2.36)a
Hypercholesterolemia 0.78 (0.70–0.90)a 0.82 (0.68–0.97)a 1.09 (0.83–1.42)
Current smoking 0.75 (0.66–0.86)a 0.57 (0.46–0.71)a 0.70 (0.50–0.97)a
Coronary artery disease 1.26 (1.08–1.46)a 1.83 (1.52–2.21)a 1.39 (1.03–1.89)a
Prior ischemic stroke 1.21 (1.02–1.43)a 1.54 (1.24–1.91)b 1.50 (1.07–2.09)b
Prior antithrombotic treatmentc 1.46 (1.30–1.64)a 1.99 (1.69–2.34)a 1.63 (1.26–2.09)a
Low GFR 2.14 (1.88–2.45)a 2.97 (2.52–3.51)a 1.86 (1.43–2.42)a
High GFR 0.54 (0.31–0.97)a 0.44 (0.14–1.43) 0.36 (0.05–2.64)
Decreasing GFR (by 10 mL/min/1.73 m2) 1.20 (1.17–1.24)a 1.33 (1.28–1.38)a 1.16 (1.02–1.22)a
Very low GFRb 2.66 (1.83–3.87)a 3.76 (2.61–5.41)a 1.19 (0.58–2.47)
Abbreviations: ECASS 5 European Cooperative Acute Stroke Study; GFR 5 glomerular filtration rate; IVT 5 IV thrombol-
ysis; mRS 5 modified Rankin Scale; NIHSS 5 NIH Stroke Scale; sICH 5 symptomatic intracranial hemorrhage.
Data are odds ratio (95% confidence interval). Very low GFR ,30 mL/min/1.73 m2; low GFR ,60 mL/min/1.73 m2; high
GFR .120 mL/min/1.73 m2.
aStatistically significant (p , 0.05).
bp , 0.1 (i.e., adjusted for in the multivariate analysis).
c Post hoc analyses, very low GFR n 5 129, poor outcome 5 88, death 5 49, sICHECASS-II 5 8.
Table 3 Multivariate analysis of primary outcomes (odds adjusted for all variables with p < 0.1 in the
univariate analysis) in patients treated with IVT
Predictors for Poor outcome Death sICHECASS-II
Age (each year) 1.05 (1.04–1.05), ,0.001 1.05 (1.04–1.07), ,0.001 NS
Sex 1.21 (1.04–1.41), 0.014 NS NS
NIHSS (each point) 1.19 (1.17–1.21), ,0.001 1.15 (1.13–1.17), ,0.001 1.05 (1.03–1.07), ,0.001
Glucose (each mg/dL) 1.09 (1.05–1.12), ,0.001 1.09 (1.05–1.14), ,0.001 NS
Diabetes mellitus 1.25 (1.001–1.55), 0.049 NS NS
Hypercholesterolemia 0.83 (0.71–0.98), 0.025 NS NS
Current smoking 1.49 (1.23–1.80), ,0.001 NS NS
Prior stroke NS 1.33 (1.004–1.77), 0.047 NS
Low GFR 1.32 (1.10–1.58), 0.003 1.73 (1.39–2.14), ,0.001 1.64 (1.21–2.23), 0.001
High GFRa 1.38 (0.69–2.79), 0.364 NS NS
Decreasing GFR
(by 10 mL/min/1.73 m2)
1.05 (1.01–1.09), 0.017 1.18 (1.11–1.24), ,0.001 1.11 (1.04–1.20), 0.003
Post hoc analyses
Very low GFRa 1.96 (1.27–3.04), 0.003 2.53 (1.65–3.87), ,0.001 NS
Abbreviations: ECASS 5 European Cooperative Acute Stroke Study; GFR 5 glomerular filtration rate; IVT 5 IV thrombol-
ysis; NIHSS 5 NIH Stroke Scale; NS 5 not significant (p . 0.05); sICH 5 symptomatic intracranial hemorrhage.
Data are odds ratio (95% confidence interval), p value. Very low GFR,30 mL/min/1.73 m2; low GFR,60 mL/min/1.73 m2;
high GFR .120 mL/min/1.73 m2.
aAdjusted only for age and NIHSS score because of the small sample size.
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Fourth, the choice of criteria for the primary outcome
measures might be considered arbitrary. Interestingly,
there were virtually no differences in the odds between
the primary (mRS scores 3–6) and the secondary func-
tional outcome measures (mRS scores 2–6) as well as
for sICH according to the ECASS-II and NINDS cri-
teria. This might be an argument for the robustness of
our findings and the prognostic importance of renal
function in IVT-treated patients.
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